The Latest Breaking News from gene editing

With their primary goal to advance scientific knowledge, most scientists are not trained or incentivized to think through the societal implications of the technologies they are developing. Even in genomic medicine, which is geared toward benefiting future patients, time and funding pressures make real-time ethics oversight difficult.

With ever-expanding operations and rapid technological innovations, the gene-editing industry looks poised for solid long-term growth. Thus, investors could consider solid stocks Eli Lilly (LLY), Sanofi (SNY), and Vertex Pharmaceuticals (VRTX). Continue reading.

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference for Wood's disruptive approach to investing, may find these stocks particularly compelling.

The biotechnology industry is thriving, fueled by solid government support, rising healthcare spending worldwide, gene editing breakthroughs, and rapid AI adoption. Hence, fundamentally solid biotech stocks Shionogi (SGIOY), United Therapeutics (UTHR), and SIGA Technologies (SIGA) could be ideal buys for potential gains. Keep reading….

Creating visually distinctive plants likely to become important as more weed-like crops are grown for food

China’s He Jiankui, who used Crispr to edit genome, says he is working on genetic diseases and suggests human embryo gene editing will one day be accepted

Explore the latest breakthroughs in genetic engineering, from CRISPR-Cas9 to gene therapy, and their impact on healthcare and conservation.

Explore how genomic innovations are revolutionizing healthcare with precision gene editing and personalized treatments.

Explore the biggest technology trends that are expected to shape our lives in the next 10 years, from AI integration and virtual reality to genetic enginee...